Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1546-1559

  Palanki, Moorthy S S ^a   Akiyama, Hideo ^b   Campochiaro, Peter ^b   Cao, Jianguo ^a   Chow, Chun P ^a   Dellamary, Luis ^a   Doukas, John ^a   Fine, Richard ^c   Gritzen, Colleen ^a   Hood, John D ^a   Hu, Steven ^a   Kachi, Shu ^b   Kang, Xinshan ^c   Klebansky, Boris ^c   Kousba, Ahmed ^a   Lohse, Dan ^a   Chi, Ching Mak ^a   Martin, Michael ^a   McPherson, Andrew ^a   Pathak, Ved P ^a   Renick, Joel ^a   Soll, Richard ^a   Umeda, Naoyasu ^b   Yee, Shiyin ^a   Yokoi, Katsutoshi ^b   Zeng, Binqi ^a   Zhu, Hong ^a   Noronha, Glenn ^a   more..

^a TargeGen Inc   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c BioPredict Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ESTER DERIVATIVE; EYE DROPS; PRODRUG; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; TG 100801; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RETINA MACULA AGE RELATED DEGENERATION; ROOM TEMPERATURE; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC CIRCULATION; THERMOSTABILITY;

ADMINISTRATION, TOPICAL; ANIMALS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EYE; LASERS; MACULAR DEGENERATION; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OPHTHALMIC SOLUTIONS; PHENOLS; PRODRUGS; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 41149110687     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7011276     Document Type: Article

References (62)

1. De Jong, P. T. Age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1474-1485.
2. Rattner, A.; Nathans, J. Macular degeneration: recent advances and therapeutic opportunities. Nat. Rev. Neurosci. 2006, 7, 860-872.
3. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature 1992, 359, 843-845.
4. Forsythe, J. A.; Jiang, B. H.; Iyer, N. V.; Faton, A.; Leung, S. W.; Koos, R. D.; Semenza, G. L. **Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16, 4604-4613.
5. Aiello, L. P.; Avery, R. L.; Arrigg, P. G.; Keyt, B. A.; Jampel, H. D.; Shah, S. T.; Pasquale, L. R.; Thieme, H.; Iwamoto, M. A.; Park, J. E.; Nguyen, H. V.; Aiello, L. M.; Ferrara, N.; King, G. L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994, 331, 1480-1487.
6. Pe'er, J.; Shweiki, D.; Itin, A.; Hemo, I.; Gnessin, H.; Keshet, E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 1995, 72, 638-645.
7. Wand, F.; Rendahl, K. G.; Manning, W. C.; Quiroz, D.; Coyne, M.; Miller, S. S. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovasculariaztion in rat. Invest. Ophthalmol. Visual Sci. 2003, 44, 781-790.
8. Reich, S. J.; Fosnot, J.; Kuroki, A.; Tang, W.; Yang, X.; Maguire, A. M.; Bennett, J.; Tolentino, M. J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vision 2003, 9, 210-216.
9. Bainbridge, J. W.; Jia, H.; Bagherzadeh, A.; Selwood, D.; Ali, R. R.; Zachary, I. A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem. Biophys. Res. Commun. 2003, 302, 793-799.
10. Aiello, L. P.; Pierce, E. A.; Foley, E. D.; Takagi, H.; Chen, H.; Riddle, L.; Ferrara, N.; King, G. L.; Smith, L. E. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10457-10461.
11. Ferrara, N.; Damico, L.; Shams, N.; Lowman, H.; Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26, 859-870.
12. Rosenfeld, P. J.; Brown, D. M.; Heier, J. S.; Boyer, D. S.; Kaiser, P. K.; Chung, C. Y.; Kim, R. Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1419-1431.
13. Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, E. S.; Kim, R. Y.; Sy, J. P.; Schneider, S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1432-1444.
14. Nguyen, Q. D.; Tatlipinar, S.; Shah, S. M.; Haller, J. A.; Quinlan, E.; Sung, J.; Zimmer-Galler, I.; Do, D. V.; Campochiaro, P. A. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 2006, 142, 961-969.
15. Fernando, N. H.; Hurwitz, H. I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004, 1, 1-18.
16. Saishin, Y.; Saishin, Y.; Takahashi, K.; Silva, R. L.;E.; Hylton, D.; Rudge, J. S.; Wiegand, S. J.; Campochiaro, P. A. VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 2003, 195, 241-248.
17. Sirna Therapeutics is currently developing an injectable form of SiRNA (Sirna-027) targeting VEGFr. Shen, J.; Samul, R.; Silva, R. L.; Akiyama, H.; Liu, H.; Saishin, Y.; Hackett, S. F.; Zinnen, S.; Kossen, K.; Fosnaugh, K.; Vargeese, C.; Gomez, A.; Bouhana, K.; Aitchison, R.; Pavco, P.; Campochiaro, P. A. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 2005, 13, 225-234.
18. Small molecules targeting VEGFr pathway for the treatment of AMD are under development at Pfizer. Beals, C. R.; Day, W. W.; Khalil, D. A.; Klamerus, K. J.; Raber, S. R.; Scassellati-Sorzolini, B.; Zwillich, S. H. Compositions Comprising Indazole Compound for Sub-Tenon Delivery. WO 2006117666, April 2006.
19. Orally delivered vatalanib is being evaluated in a phase II clinical trial along with verteporfin in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration. http://www.clinicaltrials.gov/ct/gui/show/NCT00138632.
20. Several devices are in development to deliver drugs to the back of the eye. Sultana, Y; Jain, R.; Aqil, M.; Ali, A. Curr. Drug Delivery 2006, 3, 207-217.
21. Antismoking compound mecamylamine targeting endothelial nicotinic acetylcholine receptor and pazopanib from GlaxoSmithKline targeting VEGFr are in phase I. http://clinicaltrials.gov/ct/show/NCT00463320?-order=19.
22. A VEGF trap agent from Regeneron Pharmaceuticals, Inc. and Bayer Health Care AG is in Phase II. Saishin, Y.; Saishin, Y.; Takahashi, K.; Silva, R. L.; Hylton, D.; Rudge, J. S.; Wiegand, S. J.; Campochiaro, P. A. VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell. Physiol. 2003, 195, 241-248.
23. Othera Pharmaceuticals, Inc. is developing OT-551 targeting NF-κB mediated transcriptional activation for the treatment of AM. Tanito, M.; Li, F.; Elliott, M. H; Dittmar, M.; Anderson, R. E. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest. Ophthalmol. Visual Sci. 2007, 48, 1900-1905.
24. Weis, S.; Cui, J.; Barnes, L.; Cheresh, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 2004, 167, 223-229.
25. Eliceiri, B. P.; Puente, X. S.; Hood, J. D.; Stupack, D. G.; Schlaepfer, D. D.; Huang, X. Z.; Sheppard, D.; Cheresh, D. A. Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signaling. J. Cell Biol. 2002, 157, 149-159.
26. Personal communication Martin Friedlander, Department of Cell Biology, Scripps Clinic Torry Pines 10666 North Torrey Pines Road, MS214, The Scripps Research Institute, La Jolla, CA 92037.
27. Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13, 513-609.
28. Eliceiri, B. P.; Paul, R.; Schwartzberg, P. L.; Hood, J. D.; Leng, J.; Cheresh, D. A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 1999, 4, 915-924.
29. Noronha, G.; Barrett, K.; Cao, J.; Dneprovskaia, E.; Fine, R.; Gong, X.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Wrasidlo, W.; Zeng, B.; Zhao, N. Discovery and preliminary structure activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5546-5550.
30. Noronha, G.; Barrett, K.; Boccia, A.; Brodhag, T.; Cao, J.; Chow, C. P.; Dneprovskaia, E.; Doukas, J.; Fine, R.; Gong, X.; Gritzen, C.; Gu, H.; Hanna, E.; Hood, J. D.; Hu, S.; Kang, X.; Key, J.; Klebansky, B.; Kousba, A.; Li, G.; Lohse, D.; Mak, C.; McPherson, A.; Palanki, M. S. P.; Pathak, V. P.; Renick, J.; Shi, F.; Soll, R.; Splittgerber, U.; Stoughton, S; Tang, S.; Yee, S.; Zeng, B.; Zhao, N.; Zhu., H. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo[1,2,4] triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine, a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Bioorg. Med. Chem. Lett. 2007, 17, 602-608.
31. Wolf, F. J.; Pfister, K., III; Wilson, R. M., Jr.; Robinson, C. A.; Benzotriazines, I. A new series of compounds having antimalarial activity. J. Am. Chem. Soc. 1954, 76, 3551-3553.
32. Mason, J. C.; Tennant, G. J. Chem. Soc. B 1970, 911-916.
33. Kudo, N.; Perseghini, M.; Fu, G. C. Angew. Chem., Int. Ed. 2006, 45, 1282-1284.
34. Tundel, R. E.; Anderson, K. W.; Buchwald, S. L. J. Org. Chem. 2006, 71, 430-433.
35. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999, 7, 651-66. PDB entry 1qpe.
36. Breitenlechner, C. B.; Kairies, N. A.; Honold, K.; Scheiblich, S.; Koll, H.; Greiter, E.; Koch, S.; Schafer, W.; Huber, R.; Engh, R. A. Crystal structures of active SRC kinase domain complexes. J. Mol. Biol. 2005, 353, 222-231 (PDB entries 1yom, 1yol, 1yoj).
37. After we had completed our work in the benzotriazines targeting Src, Abl, and Abl-T315I, a paper from Ariad targeting Src by utilizing the Glu310 in the back of the hydrophobic pocket by making a donor interaction was published: Dalgarno, D.; Stehle, T.; Narula, S.; Schelling, P.; Schravendijk, M. R. V.; Adams, S.; Andrade, L.; Keats, J.; Ram, M.; Jin, L.; Grossman, T.; MacNeil, I.; Metcal, C., III; Shakespeare, W.; Wang, Y.; Keenan, T.; Sundaramoorthi, R.; Bohacek, R.; Weigele, M.; Sawyer, T Chem. Biol. Drug Des. 2006, 67, 46.
38. Noronha, G.; Cao, J.; Chow, C.; Dneprovskaia, E.; Hwang, L.; Lohse, D.; Mak, C. C.; McPherson, A.; Fine, R. M.; Kang, X.; Klebansky, B.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Zeng, B. In Frontiers in Drug Design and Discovery; Caldwell, G. W., Atta-ur-Rahman, Player, M. R., Choudhary, M. I., Eds.; Bentham Science Publishers: Oak Park, IL, 2007; Vol. 3, pp121-144.
39. i value for compound 5 in VEGFr2 was 6.79 nM, and in Src it was 9.23 nM.
40. Saint-Geniez, M.; D'Amore, P. A. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int. J. Dev. Biol. 2004, 48, 1045-1058.
41. Aguilar, E.; Scheppke, L.; Dorrell, M.; Hood, J.; Dellamary, L.; Yee, S.; Friedlander, M. Topically Applied Src Kinase/VEGFR Prodrug Reduces Retinal Vascular Permeability. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, April 3 through May 4, 2006.
42. Attar, M.; Shen, J.; Ling, K, J.; Liu, D. T. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters. Expert Opin. Drug Delivery 2005, 2, 908-891.
43. Ahmed Kousba,A.; Yu, J.; Dellamary, L.; White, R.; Hu, S.; Tabak, A.; Cao, J.; Mak, C. C.; Renick, J.; McPherson, A.; Zeng, B.; Pathak, V.; Ibanez, G.; Stoughton, S.; Olafson,T.; Soll, R.; Doukas, J.; Hood, J.; Noronha, G.; Martin. M. Bioactivation and Ocular Disposition of Topically Applied Prodrug TG100801. Presented at the 8th Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics, San Diego, CA, February 9-11, 2007.
44. It is very difficult to accurately dissect sclera and choroid separately in the eyes of mice. Hence, we measured the concentration of the compound from the combined sclera and choroid tissues.
45. We examined the distribution of radiolabeled compound 12 in rabbit upon topical instillation in a single eye. The compound was present in most of the removed eye tissues and distributed in various parts of the eye as anticipated. The radiolabeled material was not present in systemic circulation or any other tissues. The bulk of the compound was excreted in the feces. It appears most of the compound was drained through the nasolacrimal drainage system. Manuscript is in preparation.
46. Miller, H.; Miller, B.; Ryan, S. J. The role of the retinal pigmented epithelium in the involution of subretinal neovascularization. Invest. Ophthalmol. Visual Sci. 1986, 27, 1644-1652.
47. Dobi, E. T.; Puliafito, C. A.; Destro, M. A new model of choroidal neovascularization in the rat. Arch. Ophthalmol. 1989, 107, 264-269.
48. Soubrane, G.; Cohen, S. Y.; Delayre, T.; Tassin, J.; Hartmann, M.-P.; Coscas, G. J.; Courtois, Y.; Jeanny, J.-C. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr. Eye Res. 1994, 13, 183-195.
49. Kimura, H.; Sakamoto, T.; Hinton, D. R.; Spee, C.; Ogura, Y.; Tabata, Y.; Ikada, Y.; Ryan, S. J. A new model of subretinal neovascularization in the rabbit. Invest. Ophthalmol. Visual Sci. 1995, 36, 2110-2119.
50. (a) Lima e Silva, R.; Kachi, S.; Akiyama, H.; Shen, J.; Hatara, M. C.; Aslam, S.; Gong, Y. Y.; Khu, N. H.; Lauer, T. W.; Hackett, S. F.; Marton, L. J.; Campochiaro, P. A. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp. Eye Res. 2006, 83, 1260-1267.
51. (b) Umeda, N.; Kachi, S.; Akiyama, H.; Zahn, G.; Vossmeyer, D.; Stragies, R.; Campochiaro, P. A. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5betal integrin antagonist. Mol. Pharmacol. 2006, 69, 1820-1828.
52. (c) Nambu, H.; Nambu, R.; Melia, M.; Campochiaro, P. A. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 2003, 44, 3650-3655.
53. (d) Takahashi, K.; Saishin, Y.; Saishin, Y.; Mori, K.; Ando, A.; Yamamoto, S.; Oshima, Y.; Nambu, H.; Melia, M. B.; Bingaman, D. P.; Campochiaro, P. A. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Visual Sci. 2003, 44, 409-415.
54. Private communication from Professor Martin Friedlander. Manuscript is in preparation.
55. Calalb, M.; Zhang, X.; Polte, T.; Hanks, S. Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem. Biophys. Res. Commun. 1996, 228, 662-668.
56. Lim, Y.; Han, I.; Jeon, J.; Park, H.; Bahk, Y.; Oh, E. Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for ras transformation of fibroblasts. J. Biol. Chem. 2004, 279, 29060-29065.
57. Eliceiri, B.; Paul, R.; Schwartzberg, P.; Hood, J. D.; Leng, J.; Cheresh, D. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 1999, 4, 915-924.
58. Abu-Ghazaleh, R.; Kabir, J.; Jia, H.; Lobo, M.; Zachary, I. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem. J. 2001, 360, 255-264.
59. Eliceiri, B. P.; Puente, X. S.; Hood, J. D.; Stupack, D. G.; Schlaepfer, D. D.; Huang, X. Z.; Sheppard, D.; Cheresh, D. A. Src-mediated coupling of focal adhesion kinase to integrin alpha. (v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 2002, 157, 149-160.
60. http://www.clinicaltrials.gov/ct/show/NCT00509548?order=1.
61. Doukas, J.; Mahesh, S.; Umeda, N.; Kachi, S.; Akiyama, H.; Yokoi, K.; Cao, J.; Chen, Z.; Dellamary, L.; Tam, B.; Racanelli-Layton, A.; Hood, J.; Martin, M.; Noronha, G.; Soll, R.; Campochiaro, P. A. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J. Cell Physiol. 2008, 215, accepted for publication.
62. Verbeke, G.; Molenberghs, G. Linear Mixed Models for Longitudinal Data; Springer-Verlag Inc.: New York, 2000; pp 93-120.